FX.co ★ China Revamps Pharma Rules Amid Drug Price Concerns

China is set to restructure its pharmaceutical pricing and procurement credit evaluation system, as reported by Yicai Global. This decision arises from escalating concerns about elevated drug prices. The National Healthcare Security Administration will implement new regulations, such as standardized evaluation documentation and a registry of non-compliant companies. Furthermore, Beijing aims to diversify the sources it uses to detect violations and will impose more severe penalties for deceitful practices, indicating a more rigorous regulatory stance towards the pharmaceutical industry.